GA-CYBLE
6.8.2024 11:03:28 CEST | Business Wire | Press release
Cyble, a global leader in AI-powered Gen 3 Cyber Threat Intelligence and digital risk protection, is excited to announce the appointment of Ernest Fung as its new Chief Financial Officer (CFO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802353537/en/
Cyble Appoints Ernest Fung as Chief Financial Officer (Photo: Business Wire)
With a rich background in corporate finance and investment strategies, Ernest brings invaluable expertise and leadership to Cyble. His role will be instrumental in enhancing the company’s financial strategy and driving its global expansion.
Ernest’s distinguished career spans over two decades across several sectors. He previously served as Chief Investment Officer at GoTo Group, Indonesia’s largest technology company. where he led GoTo’s $1 billion IPO, and secured over $1.3 billion in funding in GoTo’s pre-IPO financing. Ernest also served as Chief Investment Officer at Tokopedia, the leading e-commerce company in Indonesia, where he led the $18 billion merger with Gojek to form GoTo Group. Prior to his leadership positions at GoTo and Tokopedia, Ernest led International Corporate Development at JD.com, one of the largest e-commerce companies in China, and was a Director of Technology Investment Banking at Citigroup.
Beenu Arora, CEO of Cyble, stated, “We are delighted to welcome Ernest to our executive team. His understanding of financial strategy for managing high-growth companies will be invaluable as we scale our operations globally.”
Manish Chachada, COO of Cyble, added, “Ernest’s expertise in financial management and his strategic vision will be crucial as we expand our product offerings.”
"I am excited to join Cyble, one of the most innovative cybersecurity companies in the world," said Ernest. "I look forward to working closely with the Cyble team to achieve the company’s vision."
Cyble has recently received significant accolades, including being named an Innovation Leader in the Frost Radar™: Cyber Threat Intelligence 2024 by Frost & Sullivan. The company was also recognized in three Gartner Hype Cycle™ reports for the DRPS category, featured in Forrester's ASM Landscape 2024 report, and highlighted as a leader in G2’s Dark Web Monitoring Providers grid.
About Cyble
Cyble, the world's fastest-growing Gen 3 cyber threat intelligence company, offers comprehensive coverage across adversaries, infrastructure, exposures, weaknesses, and targets. Leveraging AI and ML, Cyble provides critical intelligence to help governments and enterprises protect citizens and infrastructure. Headquartered in Atlanta, Georgia, Cyble also has offices in Australia, Malaysia, Singapore, Dubai, Saudi Arabia, and India.
To learn more visit http://www.cyble.com/request-demo
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802353537/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom